Laser and Chronic Low Back Pain
In chronic low back pain, low level laser therapy combined with exercise is more beneficial than exercise alone in the long term: a randomised trial.
Djavid GE, Mehrdad R, Ghasemi M, Hasan-Zadeh H, Sotoodeh-Manesh A, Pouryaghoub G.
Academic Center for Education, Culture and Research, Iran.
Aust J Physiother. 2007;53(4):216.
Is low level laser therapy an effective adjuvant intervention for chronic low back pain?
Randomised trial with concealed allocation, blinded assessors and intention-to-treat analysis.
Sixty-one patients who had low back pain for at least 12 weeks.
One group received laser therapy alone, one received laser therapy and exercise, and the third group received placebo laser therapy and exercise. Laser therapy was performed twice a week for 6 weeks.
Outcomes were pain severity measured using a 10-cm visual analogue scale, lumbar range of motion measured by the Schober Test and maximum active flexion, extension and lateral flexion, and disability measured with the Oswestry Disability Index on admission to the study, after 6 weeks of intervention, and after another 6 weeks of no intervention.
There was no greater effect of laser therapy compared with exercise for any outcome, at either 6 or 12 weeks. There was also no greater effect of laser therapy plus exercise compared with exercise for any outcome at 6 weeks. However, in the laser therapy plus exercise group pain had reduced by 1.8 cm (95% CI 0.1 to 3.3, p = 0.03), lumbar range of movement increased by 0.9 cm (95% CI 0.2 to 1.8, p < 0.01) on the Schober Test and by 15 deg (95% CI 5 to 25, p < 0.01) of active flexion, and disability reduced by 9.4 points (95% CI 2.7 to 16.0, p = 0.03) more than in the exercise group at 12 weeks.
In chronic low back pain low level laser therapy combined with exercise is more beneficial than exercise alone in the long term.
Ortop Traumatol Rehabil. 2010 Jan-Feb;12(1):67-79.
|15 Apr 2012
A Clinical Study of the Effectiveness for Mitigating Pain and Improving Range of Motion with the Erchonia Low-Level Laser on Minor Neck and Shoulder Pain
A Clinical Study of the Effectiveness for Mitigating Pain and Improving Range of Motion with the Erchonia Low-Level Laser on Minor Neck and Shoulder Pain: July-Sept 2000
*Erchonia Corporation study submitted to the FDA and given market clearance January 2002.
One hundred patients were recruited to participate in a randomized, double-blind study of the temporary effects of the Erchonia low-level laser on ameliorating minor neck and shoulder pain and in improving range of motion. Individual subject-success criteria was defined as a 30% improvement in degree of pain from pre- to post-procedure measurement immediately following treatment. Forty out of the 50 test group subjects (80% of all test group subjects) met or exceeded the individual success criteria by demonstrating a 30% improvement in degree of pain rating from pre- to post-procedure measurement. Seven out of the 50 placebo group subjects (14% of all placebo group subjects) met or exceeded the individual success criteria by demonstrating a 30% improvement in degree of pain. Temporary improvements in pain levels for test patients were statistically significant at the p<0.05 level. Although not statistically significant, for the majority of patients, the reduction in degree of pain immediately after treatment by the laser was maintained or reduced further 24 hours post-treatment. Post-procedure linear range of motion measurements suggested significant improvements in range of motion for the right side of the neck and both right and left sides of shoulders. No adverse events were reported.
The Erchonia low-level laser is a safe and effective device for single-use temporary pain relief and improvement in range of motion for patients with chronic pain in the neck and shoulder areas originating from the conditions of osteoarthritis, muscle spasms and cervical and thoracic spine strain. This landmark study helped the Erchonia Corporation low level laser to become the first low level laser of any kind to be approved by the FDA.